Surgery for Craniopharyngiomas Treatment & Management

  • Author: Lawrence S Chin, MD, FACS; Chief Editor: Allen R Wyler, MD   more...
 
Updated: Oct 29, 2010
 

Medical Therapy

No primary medical therapy exists for this tumor. Hormonal replacements are administered as needed if endocrine abnormalities exist.

Next

Surgical Therapy

The initial surgical decision concerns the approach. If the predominant portion of the tumor is intrasellar, the approach is usually transsphenoidal. Often, the suprasellar component can be delivered into the sella and evacuated. Further, the transsphenoidal approach is well tolerated by patients and is preferable to a craniotomy, when feasible.[11, 12, 13, 14, 15, 16, 17, 18]

If the pituitary sella is not enlarged, the transsphenoidal approach is generally not preferred. A craniotomy is usually necessary when the predominant component is suprasellar, although certain suprasellar masses may be located through an extended transsphenoidal approach. This approach is also useful for lesions that have a relatively small suprasellar extension.

The pterional craniotomy is the standard craniotomy approach to suprasellar lesions because it allows good visualization of the optic nerves, chiasm, and surrounding structures. Variations of the pterional craniotomy have been proposed to include resection of the orbital rim and zygoma so as to provide a more defined view of the skull base and thereby allow better access to the superior aspects of this tumor. These approaches lend themselves to less frontal lobe retraction in order to visualize the operative site.

A subfrontal approach is appropriate for lesions that lie anterior to the optic chiasm, but this may be difficult to determine preoperatively. Under rare circumstances, a transcallosal approach is necessary when the tumor is entirely within the third ventricle. The drawback to this approach is the inability to identify the optic chiasm and pituitary stalk early in the dissection.

Cystic tumors are amenable to either a transsphenoidal approach or a pterional craniotomy. The solid components often adhere to the optic chiasm or hypothalamus and, therefore, may be difficult to remove in their entirety.

Cyst aspiration combined with intracavitary phosphorus-32 (32 P) instillation is an alternative to traditional surgical resection (see video below). Good long-term control of tumor growth has been demonstrated; however, a tumor with significant solid components is not likely to respond to32 P.[19]

Dissection of craniopharyngioma cyst with aspiration.

Grading

In an attempt to balance the advantages of an aggressive surgical resection against the risk of significant morbidity, a preoperative grading system (for children) has been proposed. This system considers the extent of invasion of the hypothalamus by the tumor and is as follows:[20]

  • Type 0: The tumor represents no hypothalamic involvement.
  • Type 1: The tumor distorts or elevates the hypothalamus, but the latter is still visible.
  • Type 2: The hypothalamus is no longer visible.

Consequently, some proposed that a gross total resection be attempted in type 0 and type 1 tumors and that a subtotal resection be attempted in a type 2 tumor, leaving only the hypothalamic component. Although this grading system was developed in a pediatric population, applying it to an adult population is certainly feasible. Some evidence exists, however, that the craniopharyngiomas that arise in adults are less likely to invade the hypothalamus.

A newer classification system proposed by Kassam et al uses a scheme that divides tumors according to their suprasellar extension, based upon the endoscopic expanded endonasal approach (EEA), and is as follows:[21]

  • Type I - Preinfundibular
  • Type II - Transinfundibular (extending into the stalk)
  • Type III - Retroinfundibular, extending behind the gland and stalk, and has 2 subdivisions (IIIa, extending into the third ventricle; and IIIb, extending into the interpeduncular cistern)
  • Type IV - Isolated to the third ventricle and/or optic recess and is not accessible via an endonasal approach
Previous
Next

Preoperative Details

Preoperative workup includes an endocrinologic evaluation, particularly to exclude hypoadrenalism and hypothyroidism, both of which increase surgical mortality rates. Dexamethasone may be started prior to surgery to decrease edema.[22]

Previous
Next

Intraoperative Details

Successful transsphenoidal resection of a craniopharyngioma requires a generous removal of the contents of the sella turcica. Adequate suprasellar decompression occurs when the arachnoid membrane that surrounds the tumor descends into the operative field. Cerebrospinal fluid (CSF) leakage occurs if the arachnoid is disrupted.

The goal of a craniotomy is gross total removal of the tumor with preservation of the optic apparatus and pituitary stalk. Understanding the anatomy in this region is key to accomplishing this goal. The optic chiasm is nearly always elevated, and the pituitary stalk is usually displaced posteriorly. The stalk may be identified by the striate pattern of portal vessels along its surface. The lamina terminalis may need to be opened for access into the third ventricle. The goal of tumor removal must not outweigh the need for preservation of neural structures; therefore, leaving undisturbed a tumor that is densely adherent to the optic apparatus, anterior cerebral artery, or hypothalamus is advisable.

In general, because long-term tumor control is excellent with radiation therapy following subtotal tumor removal, a conservative approach to tumor resection is usually advised.[23] In some patients, however, a good cleavage plane exists between tumor and brain, and a true complete resection can be accomplished. Surgical judgment is crucial in the assessment of this possibility.

Previous
Next

Follow-up

Performing a full postoperative endocrine evaluation as well as repeated imaging studies is advisable. MRI scans are typically obtained immediately postoperatively (within 48 h) and then at periodic intervals.

Previous
Next

Complications

The most common complications are related to injury of the adjacent neural structures. Vision may worsen because of unavoidable optic apparatus manipulation.[24]

Postoperatively, many patients demonstrate hypopituitarism. In order to offset this, they are usually given physiologic doses of hydrocortisone as well as a dexamethasone taper to decrease the edema associated with the surgical approach.

Diabetes insipidus may develop and may require treatment with fluid replacement and, occasionally, vasopressin or its synthetic analogue, desmopressin. Some patients have diabetes insipidus as well as disruption of their thirst sensation. These patients pose a difficult management problem and are at high risk for developing hypernatremia. Injuries to the hypothalamus can cause other behavioral changes, including caloric balance disturbance, memory disturbance, and changes in affective behavior.

In rare cases, development of radiation-induced gliomas may occur. This long-term complication has a latency period of greater than 10 years, frequently involves the temporal lobe, and has been predominantly reported in patients who underwent conventional fractionated radiotherapy in their childhood.[25]

Previous
Next

Outcome and Prognosis

Total resection is the best chance for cure, although some series have reported good results with subtotal resection and fractionated radiation therapy. Small residual tumor, confirmed on postoperative MRI, is generally treated with external beam radiotherapy; however, stereotactic radiosurgery has been used. The use of proton beam radiotherapy for residual disease is currently being investigated. Although the amount of radiation is limited by the proximity to the optic chiasm, good long-term results are now being reported after radiosurgery.[26, 27, 28, 29, 30]

Adverse effects of radiation therapy include endocrine dysfunction, optic neuritis, dementia, and radiation necrosis. In addition, radiation can induce tumors such as meningiomas, sarcomas, and gliomas. In pediatric cases, radiation is postponed to minimize its effects on intelligence quotient and growth. Survival rates for patients with surgery and radiation are better than with surgery alone because radiation helps deter regrowth when residual tumor is present.[31]

Brachytherapy has also been used to treat cystic craniopharyngiomas. Radioisotopes are placed into the cystic portions of the craniopharyngioma. Phosphorus-32 (32 P), colloidal gold-198, colloidal yttrium-91, and bleomycin have all been used. Bleomycin causes shrinkage of the cyst but is highly toxic to neural structures.

In a 1992 review of brachytherapy for craniopharyngiomas, Van den Berge followed 31 patients for an average of 41 months.[32] Twenty-nine percent showed improvement of visual acuity, while 13% had stable visual acuity, and 58% deteriorated. Similarly, 28% showed improvement of their visual fields, with 20% showing no change, and 52% deteriorating.

Mortality and morbidity

Overall, the surgical mortality rate is less than 5%, mostly from hypothalamic injury. Bilateral hypothalamic injuries lead to hyperthermia and somnolence. The 5-year survival rate for tumor treatment is 55-85%.

Recurrence most commonly occurs within the first year, with a few reports of recurrences after 3 years. Morbidity and mortality rates are higher with recurrences. Hoffman followed 50 children with craniopharyngiomas.[15] In his 1992 report, 90% had total excision, and tumor recurred in 34%. Of all 50 children, 56% were leading normal or nearly normal lives, often requiring endocrine replacement. Twenty-four percent were able to function reasonably well and to attend school despite intellectual, visual, or weight problems; 8% were significantly handicapped; and 6% died.

Previous
Next

Future and Controversies

The largest divide in the treatment of craniopharyngiomas regards whether to perform a gross total excision or perform a subtotal resection followed by radiation therapy. Retrospective series support both philosophies. Surgical judgment must temper the enthusiasm for gross total removal at all costs. The use of 3-dimensional conformal radiation treatment (3D CRT), stereotactic radiosurgery (SRS), stereotactic radiotherapy (SRT), and intensity-modulated radiation therapy (IMRT) will further allow treatment of small tumor residua with little risk of neurologic deficit.[33]

Previous
 
Contributor Information and Disclosures
Author

Lawrence S Chin, MD, FACS  Professor and Chairman, Department of Neurosurgery, Boston University School of Medicine; Neurosurgeon-in-Chief, Boston Medical Center

Lawrence S Chin, MD, FACS is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American Association for the Advancement of Science, American Association of Neurological Surgeons, American College of Surgeons, Children's Oncology Group, Congress of Neurological Surgeons, Phi Beta Kappa, and Society for Neuro-Oncology

Disclosure: Nothing to disclose.

Coauthor(s)

Mayur Jayarao, MD  Fellow, Department of Neurosurgery, Boston Medical Center

Mayur Jayarao, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, and Medical Council of India

Disclosure: Nothing to disclose.

Specialty Editor Board

Paul L Penar, MD, FACS  Professor, Department of Surgery, Division of Neurosurgery, Director, Functional Neurosurgery and Radiosurgery Programs, University of Vermont College of Medicine

Paul L Penar, MD, FACS is a member of the following medical societies: Alpha Omega Alpha, American Association of Neurological Surgeons, Congress of Neurological Surgeons, and World Society for Stereotactic and Functional Neurosurgery

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Ryszard M Pluta, MD, PhD  Associate Professor, Neurosurgical Department Medical Research Center, Polish Academy of Sciences at Warsaw, Poland; Clinical Staff Scientist, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH); Fishbein Fellow, JAMA, Chicago ,IL

Ryszard M Pluta, MD, PhD is a member of the following medical societies: Congress of Neurological Surgeons and Polish Society of Neurosurgeons

Disclosure: Nothing to disclose.

Paolo Zamboni, MD  Professor of Surgery, Chief of Day Surgery Unit, Chair of Vascular Diseases Center, University of Ferrara, Italy

Paolo Zamboni, MD is a member of the following medical societies: American Venous Forum and New York Academy of Sciences

Disclosure: Nothing to disclose.

Chief Editor

Allen R Wyler, MD  Former Medical Director, Northstar Neuroscience, Inc

Allen R Wyler, MD is a member of the following medical societies: American Academy of Neurological and Orthopaedic Surgeons, American Association of Neurological Surgeons, and Society of Neurological Surgeons

Disclosure: Nothing to disclose.

References
  1. Garnett MR, Puget S, Grill J, Sainte-Rose C. Craniopharyngioma. Orphanet J Rare Dis. Apr 10 2007;2:18. [Medline]. [Full Text].

  2. Hoffman HJ. Craniopharyngiomas. Can J Neurol Sci. Nov 1985;12(4):348-52. [Medline].

  3. Karavitaki N, Cudlip S, Adams CB, Wass JA. Craniopharyngiomas. Endocr Rev. Jun 2006;27(4):371-97. [Medline]. [Full Text].

  4. Rutka JT. Craniopharyngioma. J Neurosurg. Jul 2002;97(1):1-2; discussion 2. [Medline]. [Full Text].

  5. Combelles G, Ythier H, Wemeau JL, Cappoen JP, Delandsheer JM, Christiaens JL. [Craniopharyngioma in the same family]. Neurochirurgie. 1984;30(5):347-9. [Medline].

  6. Sanford RA, Muhlbauer MS. Craniopharyngioma in children. Neurol Clin. May 1991;9(2):453-65. [Medline].

  7. Fukushima T, Hirakawa K, Kimura M, Tomonaga M. Intraventricular craniopharyngioma: its characteristics in magnetic resonance imaging and successful total removal. Surg Neurol. Jan 1990;33(1):22-7. [Medline].

  8. Jagannathan J, Dumont AS, Jane JA Jr, Laws ER Jr. Pediatric sellar tumors: diagnostic procedures and management. Neurosurg Focus. Jun 15 2005;18(6A):E6. [Medline].

  9. Nelson GA, Bastian FO, Schlitt M, White RL. Malignant transformation in craniopharyngioma. Neurosurgery. Feb 1988;22(2):427-9. [Medline].

  10. Saeki N, Nagai Y, Matsuura I, et al. Histologic characteristics of normal perivascular spaces along the optic tract: new pathogenetic mechanism for edema in tumors in the pituitary region. AJNR Am J Neuroradiol. Aug 2004;25(7):1218-22. [Medline].

  11. Baskin DS, Wilson CB. Surgical management of craniopharyngiomas. A review of 74 cases. J Neurosurg. Jul 1986;65(1):22-7. [Medline].

  12. Couldwell WT, Weiss MH, Rabb C, Liu JK, Apfelbaum RI, Fukushima T. Variations on the standard transsphenoidal approach to the sellar region, with emphasis on the extended approaches and parasellar approaches: surgical experience in 105 cases. Neurosurgery. Sep 2004;55(3):539-47; discussion 547-50. [Medline].

  13. Dhellemmes P, Vinchon M. Radical resection for craniopharyngiomas in children: surgical technique and clinical results. J Pediatr Endocrinol Metab. Apr 2006;19 Suppl 1:329-35. [Medline].

  14. Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg. Feb 1999;90(2):237-50. [Medline].

  15. Hoffman HJ, De Silva M, Humphreys RP, Drake JM, Smith ML, Blaser SI. Aggressive surgical management of craniopharyngiomas in children. J Neurosurg. Jan 1992;76(1):47-52. [Medline].

  16. Norris JS, Pavaresh M, Afshar F. Primary transsphenoidal microsurgery in the treatment of craniopharyngiomas. Br J Neurosurg. Aug 1998;12(4):305-12. [Medline].

  17. Tomita T, Bowman RM. Craniopharyngiomas in children: surgical experience at Children's Memorial Hospital. Childs Nerv Syst. Aug 2005;21(8-9):729-46. [Medline].

  18. Yasargil MG, Curcic M, Kis M, Siegenthaler G, Teddy PJ, Roth P. Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. J Neurosurg. Jul 1990;73(1):3-11. [Medline].

  19. Hasegawa T, Kondziolka D, Hadjipanayis CG, Lunsford LD. Management of cystic craniopharyngiomas with phosphorus-32 intracavitary irradiation. Neurosurgery. Apr 2004;54(4):813-20; discussion 820-2. [Medline].

  20. Puget S, Garnett M, Wray A, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg. Jan 2007;106(1 Suppl):3-12. [Medline].

  21. Kassam AB, Gardner PA, Snyderman CH, Carrau RL, Mintz AH, Prevedello DM. Expanded endonasal approach, a fully endoscopic transnasal approach for the resection of midline suprasellar craniopharyngiomas: a new classification based on the infundibulum. J Neurosurg. Apr 2008;108(4):715-28. [Medline].

  22. Hopper N, Albanese A, Ghirardello S, Maghnie M. The pre-operative endocrine assessment of craniopharyngiomas. J Pediatr Endocrinol Metab. Apr 2006;19 Suppl 1:325-7. [Medline].

  23. Fischer EG, Welch K, Shillito J Jr, Winston KR, Tarbell NJ. Craniopharyngiomas in children. Long-term effects of conservative surgical procedures combined with radiation therapy. J Neurosurg. Oct 1990;73(4):534-40. [Medline].

  24. Poretti A, Grotzer MA, Ribi K, Schonle E, Boltshauser E. Outcome of craniopharyngioma in children: long-term complications and quality of life. Dev Med Child Neurol. 2004;46:220-229.

  25. Enchev Y, Ferdinandov D, Kounin G, Encheva E, Bussarsky V. Radiation-induced gliomas following radiotherapy for craniopharyngiomas: a case report and review of the literature. Clin Neurol Neurosurg. Sep 2009;111(7):591-6. [Medline].

  26. Habrand JL, Ganry O, Couanet D, et al. The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature. Int J Radiat Oncol Biol Phys. May 1 1999;44(2):255-63. [Medline].

  27. Kalapurakal JA. Radiation therapy in the management of pediatric craniopharyngiomas--a review. Childs Nerv Syst. Aug 2005;21(8-9):808-16. [Medline].

  28. Laws ER Jr, Vance ML. Radiosurgery for pituitary tumors and craniopharyngiomas. Neurosurg Clin N Am. Apr 1999;10(2):327-36. [Medline].

  29. Vernet O, Montes JL, Farmer JP, Blundell JE, Bertrand G, Freeman CR. Long term results of multimodality treatment of craniopharyngioma in children. J Clin Neurosci. May 1999;6(3):199-203. [Medline].

  30. Wara WM, Sneed PK, Larson DA. The role of radiation therapy in the treatment of craniopharyngioma. Pediatr Neurosurg. 1994;21 Suppl 1:98-100. [Medline].

  31. Paulino AC, Fowler BZ. Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol. Mar 2005;22(2):89-101. [Medline].

  32. Van den Berge JH, Blaauw G, Breeman WA, Rahmy A, Wijngaarde R. Intracavitary brachytherapy of cystic craniopharyngiomas. J Neurosurg. Oct 1992;77(4):545-50. [Medline].

  33. Hayward R. The present and future management of childhood craniopharyngioma. Childs Nerv Syst. Nov 1999;15(11-12):764-9. [Medline].

  34. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. Neurosurg Focus. Dec 15 1997;3(6):e1. [Medline].

  35. Byrne MN, Sessions DG. Nasopharyngeal craniopharyngioma. Case report and literature review. Ann Otol Rhinol Laryngol. Aug 1990;99(8):633-9. [Medline].

  36. Cushing H. The craniopharyngioma. In: Intracranial tumours. London: Bailliere, Tindall and Cox; 1932:93-98.

  37. Kobayashi T, Kida Y, Hasegawa T. Long-term results of gamma knife surgery for craniopharyngioma. Neurosurg Focus. May 15 2003;14(5):e13. [Medline].

  38. Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab. Dec 1999;84(12):4317-23. [Medline].

  39. Sano K, Mayanagi Y, Sekino H, Ogashiwa M, Ishijima B. Results of timulation and destruction of the posterior hypothalamus in man. J Neurosurg. Dec 1970;33(6):689-707. [Medline].

  40. Zenker FA. Enorm Cystenbildung im Gehirn, vom Hiranhang ausgehend. Arch Pathol Anat Physiol Klin Med. 1857;2:454-466.

Previous
Next
 
Coronal MRI shows a craniopharyngioma in the suprasellar space that causes compression of the optic nerves and chiasm.
Sagittal MRI shows a cystic craniopharyngioma in the suprasellar space with extension into the third ventricle.
Axial MRI shows a craniopharyngioma cyst that contains proteinaceous fluid in the third ventricle. The cyst fluid appears hyperintense.
Dissection of craniopharyngioma cyst with aspiration.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.